In this context, a recent study has highlighted a role for CCN1 in the development of endocrine resistance in patients with breast cancer [33], identifying it as a potential therapeutic target to overcome refractoriness to a wide-range of antiestrogen therapies. The gene discussed is CCN1; the disease is breast carcinoma.